
EPRX Stock Forecast & Price Target
EPRX Analyst Ratings
Bulls say
Eupraxia Pharmaceuticals is a biotechnology company that has a promising future due to its innovative Diffusphere technology which has shown strong potential in treating chronic conditions such as osteoarthritis and eosinophilic esophagitis. With a strong pipeline of drugs, including its lead product EP-104 which has shown promising results in clinical trials, the company is well-positioned for future success. Positive commentary and data from physicians and clinical trials, as well as the potential for expanding into new indications, make Eupraxia an attractive investment opportunity.
Bears say
Eupraxia Pharmaceuticals is facing significant challenges in gaining market acceptance for their products, with expensive, recurring treatments like mechanical dilation and short-acting steroids being the primary competitors for EoE and strictures, respectively. It will be crucial for the company to provide strong clinical data and demonstrate cost-effectiveness in order to compete with established treatments from larger companies and address potential financing and cross-border risks. With a high probability-weighted success rate for EP-104GI and a late 2028/early 2029 launch, the stock's valuation based on its DCF model is $183M, but as a negative sentiment towards competition, the 11.0% WACC shows claims that it may miss out on an appropriate timeframe in competition.
This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
EPRX Analyst Forecast & Price Prediction
Start investing in EPRX
Order type
Buy in
Order amount
Est. shares
0 shares